From: Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
177Lu-Dotatate
BSC (Octreotide LAR)
Δ
Total costs, GBP
84,990
49,289
35,701
Quality-adjusted life expectancy, QALYs
3.25
1.92
1.33
ICER, GBP per QALY gained
26,830